Millennium Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-46,455
Closed -$561K 5668
2025
Q4
$561K Sell
46,455
-371,316
-89% -$5.04M ﹤0.01% 4868
2025
Q3
$5.68M Sell
417,771
-1,094,287
-72% -$10.3M ﹤0.01% 3003
2025
Q2
$9.69M Sell
1,512,058
-1,569,795
-51% -$7.64M ﹤0.01% 2290
2025
Q1
$10.9M Buy
3,081,853
+2,487,617
+419% +$8.85M 0.01% 2094
2024
Q4
$2.25M Buy
594,236
+137,420
+30% +$647K ﹤0.01% 3543
2024
Q3
$1.48M Sell
456,816
-1,078,362
-70% -$2.42M ﹤0.01% 3966
2024
Q2
$2.92M Sell
1,535,178
-936,277
-38% -$1.81M ﹤0.01% 3196
2024
Q1
$7.02M Buy
2,471,455
+198,812
+9% +$2.6M ﹤0.01% 2519
2023
Q4
$33.5M Buy
2,272,643
+153,108
+7% +$2.35M 0.01% 1106
2023
Q3
$38.8M Buy
2,119,535
+197,904
+10% +$4.18M 0.02% 883
2023
Q2
$41.4M Buy
1,921,631
+847,021
+79% +$22.9M 0.02% 859
2023
Q1
$31.5M Buy
1,074,610
+215,195
+25% +$7.48M 0.02% 986
2022
Q4
$31.8M Sell
859,415
-61,713
-7% -$2.19M 0.02% 1084
2022
Q3
$25.9M Buy
921,128
+475,084
+107% +$11.9M 0.02% 1106
2022
Q2
$8.59M Buy
446,044
+308,803
+225% +$3.67M 0.01% 2229
2022
Q1
$1.76M Buy
+137,241
New +$3.1M ﹤0.01% 4010

Other funds holding AMLX

Millennium Management's AMLX Position: Q1 2026 in Review

Millennium Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 46,455 shares — an estimated $561K sold.

Millennium Management first reported a position in AMLX in Q1 2022 and held it in 16 quarters. The position peaked at $41.4M in Q2 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Millennium Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 46,455 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $561K.
  • Millennium Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Millennium Management's Amylyx Pharmaceuticals position peaked at $41.4M in Q2 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.